Methylphenidate (APTENSIO XR)
Central Nervous System Stimulant class · 28 generic manufacturers · 141 ANDAs filed at FDA.
$81.8M in CY2024 Part D spend1.4M claims · 292K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Methylphenidate used for?
Methylphenidate is tracked in Medicare Part D. Specific indication information is not available in our current dataset.
Is there a generic for Methylphenidate?
Yes. 141 ANDAs filed at FDA, 28 generic manufacturers currently shipping.
How much does my plan pay for Methylphenidate?
Across 329 Part D plans, Methylphenidate averages $0.123/unit (NADAC). Lowest available: $0.078/unit. Highest in distribution: $0.158/unit.
Is Methylphenidate on the FDA shortage list?
Yes. Methylphenidate is currently listed as an active FDA shortage.
6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.